- Home
- UROY vs ETON Comparison
UROY vs ETON Comparison
Compare UROY & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- ETON
- Stock Information
- Founded
- UROY 2017
- ETON 2017
- Country
- UROY Canada
- ETON United States
- Employees
- UROY N/A
- ETON N/A
- Industry
- UROY
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- UROY
- ETON Health Care
- Exchange
- UROY Nasdaq
- ETON Nasdaq
- Market Cap
- UROY 336.8M
- ETON 388.3M
- IPO Year
- UROY N/A
- ETON 2018
- Fundamental
- Price
- UROY $2.62
- ETON $17.14
- Analyst Decision
- UROY Strong Buy
- ETON Strong Buy
- Analyst Count
- UROY 2
- ETON 3
- Target Price
- UROY $4.00
- ETON $29.67
- AVG Volume (30 Days)
- UROY 3.5M
- ETON 432.9K
- Earning Date
- UROY 08-19-2025
- ETON 08-07-2025
- Dividend Yield
- UROY N/A
- ETON N/A
- EPS Growth
- UROY N/A
- ETON N/A
- EPS
- UROY N/A
- ETON N/A
- Revenue
- UROY $11,285,840.00
- ETON $58,181,000.00
- Revenue This Year
- UROY $126.69
- ETON $101.12
- Revenue Next Year
- UROY N/A
- ETON $45.71
- P/E Ratio
- UROY N/A
- ETON N/A
- Revenue Growth
- UROY N/A
- ETON 85.40
- 52 Week Low
- UROY $1.43
- ETON $3.40
- 52 Week High
- UROY $3.30
- ETON $21.48
- Technical
- Relative Strength Index (RSI)
- UROY 49.24
- ETON 69.10
- Support Level
- UROY $2.42
- ETON $13.99
- Resistance Level
- UROY $3.13
- ETON $15.73
- Average True Range (ATR)
- UROY 0.17
- ETON 0.88
- MACD
- UROY -0.04
- ETON 0.22
- Stochastic Oscillator
- UROY 22.86
- ETON 98.25
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.